Immunohistochemical localization of neuron-specific enolase in gastroenteropancreatic neuroendocrine tumors. Correlation with tissue and serum levels of neuron-specific enolase

Simpson, Shannon; Vinik, Aaron I.; Marangos, Paul J.; Lloyd, Ricardo V.

doi:10.1002/1097-0142(19841001)54:7<1364::aid-cncr2820540722>3.0.co;2-y

Cited by 41 publications

(10 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The intensity of staining ranged from moderate to strong cytoplasmic staining. The findings are similar to a study conducted by Simpson et al [17] in which all GEP NETS stained positive for NSE. According to Tzontcheva [18] NSE is present diffusely in the cytoplasm of NETs, hence it is consistently positive in most of the NETs.…”

Section: Discussionsupporting

confidence: 91%

Gastroenteropancreatic Neuroendocrine Tumours – An Institutional Experience

Joseph

2015

Int Jour of Biomed Res

View full text Add to dashboard Cite

Objectives: 1) To study the histomorphological spectrum of gastroenteropancreatic neuroendocrine tumours (GEP NETs) and to analyze it`s clinicopathological features. 2) To classify the GEP-NETs as per WHO 2010 classification system. 3) To analyze the expression of the NET marker Neuron specific enolase (NSE) in the above histomorphological spectrum. Methods: A retrospective study was done with collected cases of GEP-NET (over 7 year period). Clinical data was collected from medical records. The histopathology slides were retrieved from archives and reviewed. Immunohistochemical (IHC) studies were done with marker NSE. Results: The study included 11 cases of GEP-NETs. The age of the patients ranged from 13 to 65 years. The most common anatomic location was the appendix and colon with 3 cases each (27.27%). Most of the tumours were grade I (6 cases). None of the tumours were associated with carcinoid syndrome. Six out of eleven cases had metastasis at time of diagnosis (54.54%). IHC studies done with NSE resulted in positivity seen in all 10 cases in which it was done. Conclusions: Gastroenteropancreatic neuroendocrine tumours are rare and occur over a wide age range. Most of these tumours present late with metastasis at time of diagnosis. The most common location of these tumours was in the appendix and proximal colon. NSE is a good marker for these tumours and is beneficial in confirming the diagnosis.

show abstract

Section: Discussionsupporting

confidence: 91%

Gastroenteropancreatic Neuroendocrine Tumours – An Institutional Experience

Joseph

2015

Int Jour of Biomed Res

View full text Add to dashboard Cite

show abstract

“…According to Joseph et al and Simpson et al. NSE is diffusely expressed in the cytoplasm of all the GEPNETs (13,14). In our study NSE was done in four cases and was positive in all the cases.…”

Section: Similar To Our Study Maggard Et Al and Modlin Et Alsupporting

confidence: 45%

Clinicopathologic study of neuroendocrine tumors of gastroenteropancreatic tract: a single institutional experience

Uppin¹,

Uppin²,

Sunil³

et al. 2017

J. Gastrointest. Oncol.

View full text Add to dashboard Cite

Background: The gastroenteropancreatic neuroendocrine tumors (GEPNET) have a characteristic histologic appearance unrelated of the exact site of origin. However the behavior of these tumors are different in each of these sites. In this article we study the clinicopathological features of GEPNET. These tumors were classified and graded according to WHO 2010 criteria. The immunohistochemical (IHC) features were evaluated and the grade of the tumor was correlated with Ki67.Methods: A total of 40 cases of GEPNET diagnosed on biopsies as well as resected specimens were analyzed from January 2012 to June 2015.Results: There were 28 resected specimens and 12 biopsies. Majority of the gastric neuroendocrine tumors (NET) showed classic morphology of cells arranged in islands. There were 3 cases each of grade 1 and grade 2 and one was diagnosed as mixed adenoneuroendocrine carcinoma (MANEC). All the duodenal NET were well differentiated (grade 1). There were 8 cases in colon and rectum, of which 4 cases were grade 3 and 3 cases were grade 2. Majority of the pancreatic tumors were grade 1. The mean mitotic count along with ki67 had good correlation in NET of stomach, duodenum colon and rectum. Conclusions:The most common site was small intestine followed by pancreas. Majority of the tumors were NET G1. Tumors from colorectal region were mostly NEC G3. There was a strong correlation by spearman correlation analysis between Ki67 and mitotic count and moderate correlation between ki67 and tumor grade as well as mitotic rate and tumor grade. Ki67 was helpful in grading these tumors.

show abstract

“…In contrast, no y-enolase staining was found in British Journal of Cancer (1997) (Simpson et al, 1984;Vinores et al, 1984;Fukuda et al, 1989), and low levels of reactivity were detected in a cell line from a colon carcinoma (Reeve et al, 1986). As indicated above, we have detected ay-and yy-enolase in colon adenocarcinomas, although at a lower proportion than in normal tissue.…”

Section: Discussionmentioning

confidence: 45%

“…By immunoassay, the y-enolase subunit was detected in gastric and gut carcinoids (Tapia et al, 1981;Simpson et al, 1984;Nash et al, 1986), and in a cell line from a neuroendocrine tumour of colon (Reeve et al, 1986). In contrast, no y-enolase staining was found in British Journal of Cancer (1997) (Simpson et al, 1984;Vinores et al, 1984;Fukuda et al, 1989), and low levels of reactivity were detected in a cell line from a colon carcinoma (Reeve et al, 1986).…”

Section: Discussionmentioning

confidence: 97%

Phosphoglycerate mutase, 2,3-bisphosphoglycerate phosphatase and enolase activity and isoenzymes in lung, colon and liver carcinomas

Durany

Joseph²,

Campo³

et al. 1997

Br J Cancer

View full text Add to dashboard Cite

SummaryWe have compared the levels of phosphoglycerate mutase, 2,3-bisphosphoglycerate phosphatase and enolase activities and the distribution of their isoenzymes in normal colon, liver and lung tissues, and in colon, liver and lung adenocarcinoma, lung squamous cell carcinoma and lung carcinoid. All tumours presented higher phosphoglycerate mutase and enolase activities and lower 2,3-bisphosphoglycerate phosphatase activity than the normal tissues. No changes were observed in the phosphoglycerate mutase isoenzyme patterns analysed by cellulose acetate electrophoresis. All specimens contained mainly type BB isoenzyme, traces of type MB isoenzyme and no type MM isoenzyme. However, the tumours had decreased levels of 2,3-bisphosphoglycerate mutase and 2,3-bisphosphoglycerate mutase-phosphoglycerate mutase hybrid enzyme. Determined by agarose gel electrophoresis, aa-enolase was the isoenzyme predominant in normal lung, colon and liver tissue, although ay-and yy-enolase were also present in all tissues. In colon, liver and non-endocrine lung tumours, the proportions of ay-and yy-enolase decreased. In contrast, in carcinoid tumours of the lung, the proportions of these isoenzymes increased.Keywords: 2,3-bisphosphoglycerate mutase; 2,3-bisphosphoglycerate phosphatase; enolase; phosphoglycerate mutase; isoenzyme; lung, colon and liver adenocarcinoma; lung squamous cell carcinoma; lung carcinoid Phosphoglycerate mutase (D-phosphoglycerate 2,3-phosphomutase, EC 5.4.2.1, PGM) and enolase (2-phospho-D-glycerate hydrolyase, EC 4.2.1.11) are glycolytic enzymes that catalyse consecutive reversible reactions connecting the two ATP-generating reactions in the glycolytic pathway. PGM catalyses the conversion of 3-phosphoglycerate, product of the first ATP-generating reaction, into 2-phosphoglycerate in the presence of the cofactor 2,3-bisphosphoglycerate. Enolase catalyses the conversion of 2-phosphoglycerate into phosphoenolpyruvate, substrate of the second ATP-generating reaction. In addition to the main mutase activity, PGM possesses collateral 2,3-bisphosphoglycerate synthase or 2,3-bisphosphoglycerate mutase activity (BPGM: 1,3-bisphosphoglycerate + 3-phosphoglycerate -> 3-phosphoglycerate + 2,3-bisphosphoglycerate) and 2,3-bisphosphoglycerate phosphatase activity (BPGP: 2,3-bisphosphoglycerate --3-phosphoglycerate + Pi), which is stimulated by 2-phosphoglycolate (for reviews, see Fothergill-Gilmore and Watson, 1989;Wold, 1971).In mammalian tissues, there are three isoenzymes of PGM, which result from the homodimeric and the heterodimeric combinations of two different subunits coded by separate genes and designated M (muscle) and B (brain). In early fetal life, type BB-PGM is the only form present. During myogenesis, the isoenzyme phenotype undergoes transition, type BB-PGM being replaced by the MM-form, through the MB isoenzyme. In skeletal muscle, there is an almost complete transition from the BB-to the MM-PGM, but in heart muscle complete transition does not occur (Omenn and Cheung, Omenn and Hermodson, 1975;Adamson, 1...

show abstract

Immunohistochemical localization of neuron-specific enolase in gastroenteropancreatic neuroendocrine tumors. Correlation with tissue and serum levels of neuron-specific enolase

Cited by 41 publications

References 21 publications

Gastroenteropancreatic Neuroendocrine Tumours – An Institutional Experience

Gastroenteropancreatic Neuroendocrine Tumours – An Institutional Experience

Clinicopathologic study of neuroendocrine tumors of gastroenteropancreatic tract: a single institutional experience

Phosphoglycerate mutase, 2,3-bisphosphoglycerate phosphatase and enolase activity and isoenzymes in lung, colon and liver carcinomas

Contact Info

Product

Resources

About